SuperworthCytomX Therapeutics shares outstanding CTMX
Diluted shares outstanding, averaged over each quarter, from 2014.
- Latest quarter, to Jun 30, 2026
- 218.9M
- On a year earlier
- +69.6%
- more shares
CytomX Therapeutics had 218.9M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 69.6% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 169.3M | +98% |
| FY2024 | 85.7M | +5% |
| FY2023 | 81.5M | +23% |
| FY2022 | 66.1M | +1% |
| FY2021 | 65.3M | +40% |
| FY2020 | 46.6M | +3% |
| FY2019 | 45.5M | +1% |
| FY2018 | 45M | +17% |
| FY2017 | 38.4M | +5% |
| FY2016 | 36.4M | +3300% |
| FY2014 | 1.1M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 218.9M | +70% | |
| Q1 FY26 | 177.3M | +103% | |
| Q4 FY25 | 169.3M | +98% | |
| Q3 FY25 | 165M | +94% | |
| Q2 FY25 | 129.1M | +52% | |
| Q1 FY25 | 87.2M | +5% | |
| Q4 FY24 | 85.7M | +5% | |
| Q3 FY24 | 85.2M | +5% | |
| Q2 FY24 | 84.9M | +28% | |
| Q1 FY24 | 82.6M | +25% | |
| Q4 FY23 | 81.5M | +23% | |
| Q3 FY23 | 81M | +23% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on CytomX Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.